Inimmune Presents Late-Breaking Phase 1 INI-4001 Results Demonstrating On-Target Immune Activation in Advanced Solid Tumors at SITC 2026
Study demonstrated no dose-limiting toxicities and dose-responsive cytokine production consistent with TLR7/8 engagement Results support continued clinical development of INI-4001 as a potential monotherapy and in combination with other cancer treatments Missoula, MT — November 6, 2026 —— Inimmune, a clinical-stage biotechnology company developing novel immunotherapies, vaccine adjuvants and other immune-modulating technologies, today announced Phase […]
